Abstracts tagged "SLE"

Abstract Number: 773 • 2018 ACR/ARHP Annual Meeting
Exploring the Relation between Immunoglobulins Level and Infection Risk in Adult Patients with Systemic Lupus Erythematosus
Ibrahim Almaghlouth^1,2, Jiandong Su³, Eleanor Pullenayegum⁴, Sindhu Johnson⁵, Dafna D Gladman³ and Murray Urowitz⁶, ¹Division of Rheumatology, Department of medicine, King Saud University, King Khalid University Hospital, Riyadh, Saudi Arabia, ²Division of Rheumatology, Department of medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, ON, Canada, ⁵Rheumatology, Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, ⁶Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Infection is a major cause of mortality in all stages of disease in systemic lupus erythematosus (SLE). Several risk factors for infection have been…
Abstract Number: 1389 • 2018 ACR/ARHP Annual Meeting
Depression and the Patient Reported Outcomes Measurement Information System in Systemic Lupus Erythematosus
Brett Dietz¹, Patricia Katz¹, Maria Dall'Era², Louise Murphy³, Cristina Lanata¹, Laura Trupin¹ and Jinoos Yazdany², ¹University of California San Francisco, San Francisco, CA, ²University of California, San Francisco, San Francisco, CA, ³Arthritis Program, Centers for Disease Control and Prevention, Atlanta, GA
Background/Purpose: Health-related quality of life (HRQoL) is reduced in SLE. Depression is a possible contributor to reduced HRQoL. The relationship between major depression and HRQoL…
Abstract Number: 2093 • 2018 ACR/ARHP Annual Meeting
Glucocorticoid-Induced Leucine Zipper (GILZ) Deficiency Worsens Autoimmunity in the Lyn-Deficient Murine Model of Lupus By Disinhibiting the Type I Interferon (IFN) Pathway
Champa Nataraja¹, Eric Morand¹, Jacinta Lee¹, Taylah Bennett¹, Jacqueline Flynn¹, James Harris¹ and Sarah Jones², ¹Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ²School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia
Background/Purpose: Systemic lupus erythematosus (SLE) is a multi-system autoimmune disease associated with B cell hyperactivity driven by dysregulated type I IFN. Lyn-deficient mice develop lupus-like…
Abstract Number: 2630 • 2018 ACR/ARHP Annual Meeting
Complement C4d Split Products in Combination with Lupus Anticoagulant and Low Complement Associate with Thrombosis in Systemic Lupus Erythematosus
Michelle Petri¹, John Conklin², Robert Apilado², Tyler O'Malley², JoAnne Ligayon², Leilani Wolover² and Thierry Dervieux², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Exagen Diagnostics, Inc., Vista, CA
Background/Purpose: Lupus anticoagulant (LAC) is an established risk factor for thrombosis in systemic Lupus erythematosus (SLE). Emerging data suggest that activation of the complement system…
Abstract Number: 108 • 2018 ACR/ARHP Annual Meeting
Sex-Specific Expression of CXorf21 Provide Molecular Explanation for the Fundamental Difference in Male and Female Immune Response: An Explanation for Female-Bias SLE Pathogenesis
R. Hal Scofield¹, Valerie M Harris², Biji T. Kurien³ and Kristi A. Koelsch⁴, ¹Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Section of Endocrinology and Diabetes, University of Oklahoma Health Sciences Center, Okalahoma City, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is complex autoimmune disorders characterized by B cell hyperactivity resulting in autoantibody and cytokine production. Approximately 90% of patients are…
Abstract Number: 774 • 2018 ACR/ARHP Annual Meeting
Clinical Variables and Serologic Markers of Disease Activity Do Not Aid in Early Recognition of Patients with Tubulointerstitial Disease Who Have No Significant Renal Impairment at Time of Biopsy
Alejandra Londono Jimenez¹, Beatrice Goilav², Maria Salgado Guerrero³, Kimberly A. Lynch⁴, Wenzhu B. Mowrey² and Anna R. Broder⁵, ¹Rheumatology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³Internal Medicine, Jacobi Medical Center, Bronx, NY, ⁴Internal Medicine, Montefiore Medical Center, Bronx, NY, ⁵Rheumatology-Forchheimer 701N, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY
Background/Purpose: Tubulointerstitial damage (TID), defined as tubulointerstitial inflammation (TII) or interstitial fibrosis/tubular atrophy/ (IF/TA) is associated with poor renal outcomes in lupus nephritis (LN)1. Glomerular…
Abstract Number: 1400 • 2018 ACR/ARHP Annual Meeting
Effects of Childhood-Onset SLE on Academic Achievements and Employment in Adult Life
Noortje Groot¹, Marc Bijl², Radboud J. E. M. Dolhain³, Els J. Zirkzee⁴, Ruth D.E. Fritsch-Stork⁵, Y.K. Onno Teng⁶, Karina de Leeuw⁷, Irene E.M. Bultink⁸ and Sylvia S.M. Kamphuis⁹, ¹Paediatric Rheumatology, Erasmus Medical Centre - Sophia Children's Hospital, Rotterdam, Netherlands, ²Internal Medicine and Rheumatology, Martini Hospital, Groningen, Netherlands, ³Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ⁴Department of Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁵Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁶Department of Nephrology, Leiden University Medical Center, Leiden, the Netherlands, Leiden, Netherlands, ⁷Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ⁸Rheumatology, Amsterdam Rheumatology and immunology Center | VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ⁹Pediatric Rheumatology, Sophia Children's Hospital – Erasmus University Medical Center, Rotterdam, Netherlands
Background/Purpose: To investigate the effects of cSLE on education, vocation and employment in a large cohort of adults with cSLE. Methods: Patients were seen by…
Abstract Number: 2101 • 2018 ACR/ARHP Annual Meeting
UV-Induced Skin Inflammation Is Exacerbated in Lupus-Prone Ro60 Knockout Female Mice with Interferon Priming
Masaoki Kawasumi¹, Daiki Rokunohe¹, Xizhang Sun², Lena Tanaka², Sladjana Skopelja-Gardner³, Edward Chiou², Anne Davidson⁴, Sandra L. Wolin⁵ and Keith B. Elkon², ¹Medicine/Dermatology, University of Washington, Seattle, WA, ²Medicine/Rheumatology, University of Washington, Seattle, WA, ³University of Washington, Seattle, WA, ⁴Feinstein Institute for Medical Research, Manhasset, NY, ⁵National Cancer Institute, Frederick, MD
Background/Purpose: Photosensitivity is a major symptom of lupus, and excessive sunlight can cause skin rashes and flares of disease activity in systemic lupus erythematosus (SLE).…
Abstract Number: 2633 • 2018 ACR/ARHP Annual Meeting
Disease Activity, Organ Damage and Patient-Reported Outcome Measures in Swedish Patients with Recent-Onset SLE
Rebecca Heijke¹, Mathilda Björk¹, Martina Frodlund¹, Laura McDonald², Evo Alemao³ and Christopher Sjöwall¹, ¹Linköping University, Linköping, Sweden, ²Bristol-Myers Squibb, Uxbridge, United Kingdom, ³Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Patient (pt)-reported outcome measures (PROMs) are important to inform shared decision-making between pts with SLE and physicians.1 Established measures of disease activity and organ…
Abstract Number: 328 • 2018 ACR/ARHP Annual Meeting
Implementation of Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) Documentation in Systemic Lupus Erythematosus (SLE) Patients at an Academic Medical Center
Sarah H. Chung¹, Hsin-Hsuan Juo², Jenna Thomason¹ and Alison Bays³, ¹Division of Rheumatology, University of Washington, Seattle, WA, ²rheumatology, University of Washington, seattle, WA, ³Rheumatology, University of Washington, Seattle, WA
Background/Purpose: The 2008 European League Against Rheumatism (EULAR) Task Force on SLE management encourages the use of at least one of the SLE disease indices…
Abstract Number: 778 • 2018 ACR/ARHP Annual Meeting
Rates of Herpes Zoster Virus Infection in SLE Patients on Immunosuppression
Inessa Gendlina¹, Alejandra Londono Jimenez², Kimberly A. Lynch², Wenzhu B. Mowrey³, Yevgeniy Balagula⁴ and Anna R. Broder⁵, ¹Infectious Disease, Albert Einstein College of Medicine, Bronx, NY, ²Internal Medicine, Montefiore Medical Center, Bronx, NY, ³Albert Einstein College of Medicine, Bronx, NY, ⁴Medicine/Dermatology, Montefiore Medical Systems, Bronx, NY, ⁵Rheumatology-Forchheimer 701N, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY
Background/Purpose: Increased incidence of herpes zoster (HZ) has been reported in patients with autoimmune diseases. SLE in particular is known to be associated with a…
Abstract Number: 1405 • 2018 ACR/ARHP Annual Meeting
Assessment of the Psychometric Properties of Patient-Reported Outcomes of Depression in SLE
Andrew Kwan¹, Sherief Marzouk², Helia Ghanean², Michelle Vitti³, Kishwar Ali³, Dennisse Bonilla³, Nicole Anderson³, Jiandong Su³ and Zahi Touma³, ¹Faculty of Medicine, Queen's University, Kingston, ON, Canada, ²Psychiatry, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Mood disorders, including depression, are amongst the most common manifestations of neuro-psychiatric SLE. Currently, the screening and diagnosis for depression in ambulatory settings are…
Abstract Number: 2103 • 2018 ACR/ARHP Annual Meeting
Using a Drosophila Model to Unravel the Genetic Complexity of Systemic Lupus Erythematosus
Nathan Mortimer, Mary Fischer, Ashley Waring and Victoria DeMichel, School of Biological Sciences, Illinois State University, Normal, IL
Background/Purpose: The objective of our research is to understand the genetic architecture and molecular mechanisms that contribute to the development and progression of the autoimmune…
Abstract Number: 2655 • 2018 ACR/ARHP Annual Meeting
SLE-Key® Ruleout Testing in Support of Patient Triage in the Clinical Rheumatology Setting
Steve Wallace¹, Giovani Geslani², Joanna Geslani², Michael Strachan³, Don Thomas⁴, Korey Ullrich⁵, Alvin F. Wells⁶, Emileigh Wong¹, Maggie Barton¹ and Pennina Safer⁷, ¹ImmunArray Inc., Richmond, VA, ²Rheumatology Associates Arlington, Arlington, TX, ³Premier Healthcare Associates, Richmond, VA, ⁴Arthritis & Pain Associates of P. G. County, Greenbelt, MD, ⁵Rheumatology Associates of South Florida, Boca Raton, FL, ⁶Rheumatology and Immunotherapy Center, Franklin, WI, ⁷ImmunArray Ltd., Rehovot, Israel, Rehovot, Israel
Background/Purpose: SLE diagnosis and classification can be challenging. The low incidence of SLE limits primary care physician experience with the disease, but the impact of…
Abstract Number: 348 • 2018 ACR/ARHP Annual Meeting
Psychometric Validation of the Arthritis Helplessness Index in Systemic Lupus Erythematosus
Shadi Gholizadeh¹, Desiree R Azizoddin², Sarah D. Mills³, Geraldine Zamora Racaza⁴, Hi'Ilani Mary Kala'aukahi Potemra⁵, Daniel J. Wallace⁶, Michael Weisman⁷ and Perry M. Nicassio⁸, ¹SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, ²Department of Anesthesiology, Stanford University School of Medicine, Palo Alto, CA, ³Medicine, Lineberger Comprehensive Cancer Center University of North Carolina, Durham, NC, ⁴Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁵University of California, Los Angeles, Los Angeles, CA, ⁶Geffen School of Medicine at UCLA, West Hollywood, CA, ⁷Harbor UCLA Medical Center, Los Angeles, CA, ⁸Cousins Center for PNI, UCLA, LA, CA
Background/Purpose: Helplessness is a relevant construct in systemic lupus erythematosus (SLE), an unpredictable chronic illness with no known cure characterized by relapsing and remitting features.…

« Previous Page
1
…
5
6
7
8
9
…
38
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].